PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced an ...

This was the stock's second consecutive day of gains.

Pfizer Inc. closed $4.65 short of its 52-week high ($31.54), which the company reached on July 30th.

The Nasdaq dropped almost 2% and the S&P 500 lost 1%. Traders see potential for fewer rate cuts this year after the latest ...

NEW YORK, NY / ACCESSWIRE / January 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo ...

Both in their mid-twenties, the two men set up what was initially a fine chemicals business in a Brooklyn factory, using a loan from Pfizer’s father as capital. The company’s first product ...

Truist Financial decreased their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Bank of Americ ...

Jefferies investment banker Chris Roop discussed the Big Pharma M&A outlook with Business Insider. Check out the types of ...

incorporated in the year 1950, is a Large Cap company (having a market cap of Rs 23,895.64 Crore) operating in Pharmaceuticals sector. Pfizer Ltd. key Products/Revenue Segments include Pharmaceuticals ...

We see every single bet.' ...

Fresh from the $43 billion acquisition of antibody-drug conjugate (ADC) specialist Seagen, Pfizer has laid out plans ... That shift could protect the company from some of the price-cutting ...